ATE363891T1 - Injizierbare suspensionen mit verbesserten einspritzungseigenschaften - Google Patents

Injizierbare suspensionen mit verbesserten einspritzungseigenschaften

Info

Publication number
ATE363891T1
ATE363891T1 AT01928628T AT01928628T ATE363891T1 AT E363891 T1 ATE363891 T1 AT E363891T1 AT 01928628 T AT01928628 T AT 01928628T AT 01928628 T AT01928628 T AT 01928628T AT E363891 T1 ATE363891 T1 AT E363891T1
Authority
AT
Austria
Prior art keywords
suspension
viscosity
injectable compositions
injectable suspensions
injection properties
Prior art date
Application number
AT01928628T
Other languages
English (en)
Inventor
J Ramstack
M Riley
Stephen Zale
Joyce Hotz
Olufunmi Johnson
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24310496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE363891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE363891T1 publication Critical patent/ATE363891T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01928628T 2000-05-25 2001-04-19 Injizierbare suspensionen mit verbesserten einspritzungseigenschaften ATE363891T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/577,875 US6495164B1 (en) 2000-05-25 2000-05-25 Preparation of injectable suspensions having improved injectability

Publications (1)

Publication Number Publication Date
ATE363891T1 true ATE363891T1 (de) 2007-06-15

Family

ID=24310496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928628T ATE363891T1 (de) 2000-05-25 2001-04-19 Injizierbare suspensionen mit verbesserten einspritzungseigenschaften

Country Status (26)

Country Link
US (7) US6495164B1 (de)
EP (4) EP1283699B1 (de)
JP (1) JP4502355B2 (de)
KR (1) KR100810480B1 (de)
CN (1) CN100453067C (de)
AT (1) ATE363891T1 (de)
AU (2) AU2001255463B2 (de)
BG (1) BG66023B1 (de)
BR (1) BRPI0111060B8 (de)
CA (1) CA2406536C (de)
CY (3) CY1107441T1 (de)
CZ (1) CZ301359B6 (de)
DE (1) DE60128798T2 (de)
DK (3) DK1754469T3 (de)
ES (3) ES2572877T3 (de)
HU (1) HU228587B1 (de)
IL (1) IL152767A (de)
IS (1) IS2471B (de)
MX (1) MXPA02011543A (de)
NO (1) NO334660B1 (de)
NZ (1) NZ522335A (de)
PL (1) PL204298B1 (de)
PT (2) PT2269577E (de)
RU (1) RU2002135641A (de)
SI (2) SI2269577T1 (de)
WO (1) WO2001091720A2 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
KR100525189B1 (ko) * 2002-10-10 2005-10-31 메디칸(주) 고체를 이용한 생체 부피 대체를 위한 주사용 소재
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1589901A4 (de) * 2002-12-20 2006-08-09 Generipharm Inc Intrakutane injektion
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US20040247672A1 (en) * 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US7169180B2 (en) * 2003-09-03 2007-01-30 Brennan William A System and method for breast augmentation
AU2004267956B2 (en) * 2003-09-03 2010-09-16 Miscon Trading S.A. Methods for the treatment of endometriosis
US8092527B2 (en) * 2003-09-03 2012-01-10 Brennan William A System and method for breast augmentation
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
US7906125B2 (en) * 2003-09-18 2011-03-15 Boston Scientific Scimed, Inc. Solid or semi-solid therapeutic formulations
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
EP1681065A4 (de) * 2003-10-31 2011-12-28 Wakamoto Pharma Co Ltd Zusammensetzung auf wasserbasis mit reversibler thermogelierung
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
CN1968700A (zh) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
EP1679065A1 (de) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US8263109B2 (en) * 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP1948271B1 (de) 2005-11-17 2013-10-02 Zogenix, Inc. Abgabe von viskosen formulierungen durch nadellose injektion
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
EP2152315B1 (de) 2007-05-25 2016-01-06 Indivior UK Limited Formulierungen von risperidon-verbindungen mit verzögerter freisetzung
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
EP2170287B1 (de) * 2007-07-26 2013-11-06 Aqtis IP BV Pcl enthaltende mikroteilchen und ihre verwendungen
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
WO2009056990A2 (en) * 2007-08-21 2009-05-07 Actavis Group Ptc Ehf Paliperidone polymorphs
US9987221B2 (en) * 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
MX2010004366A (es) * 2007-11-05 2010-05-05 Bausch & Lomb Materiales inmiscibles en agua como vehiculos para suministro de farmacos.
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US20110118189A1 (en) 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP2306991B1 (de) * 2008-06-27 2019-12-25 Tepha, Inc. Verbesserte injektionsabgabe von mikroteilchen und zusammensetzungen dafür
EP3685837A1 (de) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Formulierungen mit verzögerter freisetzung unter verwendung nichtwässriger träger
US20100063879A1 (en) * 2008-09-05 2010-03-11 Yellowpages.Com Llc Systems and Methods to Selectively Provide Information Based on User Interest
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
WO2011100692A1 (en) 2010-02-15 2011-08-18 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6117811B2 (ja) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド 糖尿病を処置するための製剤
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
HUE043998T2 (hu) 2012-09-17 2019-09-30 Pfizer Eljárás terápiás nanorészecskék elõállítására
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9446056B2 (en) * 2014-02-11 2016-09-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
EP3116547B1 (de) 2014-03-14 2019-06-05 Pfizer Inc Therapeutische nanopartikel mit einem behandlungsmittel sowie verfahren zur herstellung und verwendung davon
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
WO2016033384A1 (en) * 2014-08-28 2016-03-03 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017007873A (es) 2014-12-15 2017-11-06 Univ Johns Hopkins Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares.
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
US20160303281A1 (en) 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
CN122124319A (zh) 2015-05-29 2026-06-02 雷夫生物股份有限公司 用于粘着到表面的组合物及方法
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016198351A1 (en) 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN105310980A (zh) * 2015-10-09 2016-02-10 北京万全德众医药生物技术有限公司 帕利哌酮缓释混悬口服液及其制备方法
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
DK3419572T3 (da) 2016-02-26 2026-06-29 Massachusetts Gen Hospital Systemer og fremgangsmåder til fremstilling og administrering af medicinsk isopslæmning
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
EP3515408A1 (de) 2016-09-23 2019-07-31 Delpor, Inc. Stabile zusammensetzungen für inkretin-mimetische verbindungen
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3600258A1 (de) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Olanzapinformulierungen mit verzögerter freisetzung
MX2019011242A (es) 2017-03-23 2020-01-21 Graybug Vision Inc Farmacos y composiciones para el tratamiento de trastornos oculares.
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
EP4717317A3 (de) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-verknüpfte degrone und degronimere zum proteinabbau
US10568842B2 (en) * 2017-08-18 2020-02-25 Lance L. Gooberman Anti-inflammatory pharmaceutical compositions and methods of administration
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
EP3841086B1 (de) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
BR112021006747A2 (pt) 2018-10-15 2021-07-13 Chong Kun Dang Pharmaceutical Corp. composições injetáveis de micropartícula de naltrexona de longa ação
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
WO2020249818A1 (en) * 2019-06-14 2020-12-17 Advanced Accelerator Applications Method of treating cancer by intratumoral deposition of radioactive microparticles
WO2021138646A1 (en) * 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー／エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
BR102020021181A2 (pt) * 2020-10-16 2022-04-26 Ipanema Industria De Produtos Veterinarios Ltda Microssuspensão contra parasitas e método para sua obtenção
BE1028769B1 (nl) * 2020-11-02 2022-05-31 Flanders Color Nv Watergedragen vloeibare spoellak
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
US20240000772A1 (en) * 2021-03-15 2024-01-04 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템
EP4366726A1 (de) 2021-07-06 2024-05-15 Mark Hasleton Behandlung des serotonin-wiederaufnahmehemmer-entzugssyndroms
CN114146020B (zh) * 2022-02-10 2022-04-29 中国远大集团有限责任公司 一种注射美容产品及其制备方法和应用
WO2024227165A1 (en) * 2023-04-28 2024-10-31 Boston Scientific Scimed, Inc. Suspensions of radiopaque crosslinked hydrogel particles in carrier fluids containing biocompatible hydrophilic polymers
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (de) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3700215A (en) * 1970-10-21 1972-10-24 Hardman Inc Mixing and dispensing device
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
IL51791A0 (en) * 1976-04-14 1977-05-31 Exxon Research Engineering Co New injectable medicinal compositions
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
AU2810189A (en) 1987-10-30 1989-05-23 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US6537574B1 (en) * 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
EP0632820B1 (de) 1992-02-28 2000-05-17 Collagen Corporation Hochkonzentrierte homogenisierte kollagenzusammensetzungen
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
ZA932272B (en) 1992-03-30 1993-10-19 Alza Corp Viscous suspensions of controlled-release drug particles
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
EP0669128B1 (de) 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
MY113268A (en) * 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2000039867A (ja) * 1998-05-18 2000-02-08 Fujitsu Ltd プラズマディスプレイ装置およびプラズマディスプレイパネルの駆動方法
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
CA2382577C (en) 1999-08-27 2008-01-22 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability

Also Published As

Publication number Publication date
MXPA02011543A (es) 2004-08-12
IS2471B (is) 2008-12-15
IS6595A (is) 2002-10-28
PT2269577E (pt) 2016-06-14
IL152767A (en) 2008-12-29
IL152767A0 (en) 2003-06-24
EP3095442A1 (de) 2016-11-23
US20080044478A1 (en) 2008-02-21
CY1107441T1 (el) 2012-12-19
BR0111060A (pt) 2003-04-15
JP4502355B2 (ja) 2010-07-14
HK1054319A1 (en) 2003-11-28
CA2406536C (en) 2009-12-22
US20080044485A1 (en) 2008-02-21
EP1283699A2 (de) 2003-02-19
AU5546301A (en) 2001-12-11
WO2001091720A3 (en) 2002-05-23
US20140193507A1 (en) 2014-07-10
HU228587B1 (en) 2013-04-29
HUP0302283A3 (en) 2007-02-28
NO20025164L (no) 2002-11-25
US6667061B2 (en) 2003-12-23
CZ20023848A3 (cs) 2003-05-14
CN100453067C (zh) 2009-01-21
DK1283699T3 (da) 2007-10-01
US20100303900A1 (en) 2010-12-02
WO2001091720A2 (en) 2001-12-06
ES2572877T3 (es) 2016-06-02
DK2269577T3 (en) 2016-06-27
RU2002135641A (ru) 2004-07-20
AU2001255463B2 (en) 2004-11-04
CN1430501A (zh) 2003-07-16
DE60128798T2 (de) 2007-10-31
KR20030020285A (ko) 2003-03-08
ES2286118T3 (es) 2007-12-01
NO334660B1 (no) 2014-05-12
EP2269577A3 (de) 2011-11-30
EP3095442B1 (de) 2020-11-18
EP1283699B1 (de) 2007-06-06
HK1152660A1 (en) 2012-03-09
BG107288A (bg) 2003-06-30
EP1754469B1 (de) 2016-03-23
BG66023B1 (bg) 2010-11-30
SI2269577T1 (sl) 2016-09-30
SI1754469T1 (sl) 2016-09-30
US6495164B1 (en) 2002-12-17
US20040208938A1 (en) 2004-10-21
US20030113380A1 (en) 2003-06-19
JP2003534366A (ja) 2003-11-18
CA2406536A1 (en) 2001-12-06
EP2269577A2 (de) 2011-01-05
BRPI0111060B1 (pt) 2019-04-16
HK1056321A1 (zh) 2004-02-13
CZ301359B6 (cs) 2010-01-27
DE60128798D1 (de) 2007-07-19
PL204298B1 (pl) 2009-12-31
ES2574823T3 (es) 2016-06-22
HK1103346A1 (en) 2007-12-21
HUP0302283A2 (hu) 2003-10-28
PL365195A1 (en) 2004-12-27
DK1754469T3 (en) 2016-06-27
EP2269577B1 (de) 2016-03-16
BRPI0111060B8 (pt) 2021-05-25
US7371406B2 (en) 2008-05-13
NO20025164D0 (no) 2002-10-28
EP1754469A1 (de) 2007-02-21
KR100810480B1 (ko) 2008-03-07
CY1117652T1 (el) 2017-05-17
US7799345B2 (en) 2010-09-21
NZ522335A (en) 2003-08-29
CY1117734T1 (el) 2017-05-17
PT1283699E (pt) 2007-06-22

Similar Documents

Publication Publication Date Title
DE60128798D1 (de) Injizierbare suspensionen mit verbesserten einspritzungseigenschaften
AR047652A1 (es) Una composicion para utilizarse en el lavado o tratamiento de telas
AR017264A1 (es) Agente blanqueador
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
BR0107052A (pt) Processo de fratura de reservatório em tempo real
CO5200807A1 (es) Composiciones de almidon procesables por fusion y fibra o filamento que comprennde almidon
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
NO20023155D0 (no) Fremgangsmåte for endring av relativ permeabilitet til en hydrokarbon-b¶rende formasjon
WO2002038185A3 (en) Injectable sustained release delivery system with loperamide
BR9809483A (pt) Composição de reticulação, processo para faze-la, e, uso da mesma.
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
AR048681A1 (es) Composiciones blanqueadoras liquidas
TR25273A (tr) Sulu kaplama bilesimleri
BR0214602A (pt) Método de produção de um tablete detergente, tablete detergente, e, componente de argila adequado para uso em uma formulação detergente
AR054348A1 (es) Metodos para usar resinas en formaciones subterraneas
PT1123794E (pt) Componente de plastico de elevado grau de enchimento
DE60224449D1 (de) Gebrauchsfertige paracetamol injektionslösungen enthaltend propylenglykol als einziges cosolvens
BR0013120A (pt) Detergente lìquido não-aquoso, com partìculas de enchimento de baixa densidade, solúveis em água de lavagem
AR008442A1 (es) Composiciones suavizadoras liquidas de telas y metodos para proveer cuidado del color
BR0013266A (pt) Composição, utilização de uma composição e artigo acabado
AR031338A1 (es) El uso de una solucion de un copolimero cationico con alto contenido de solidos en formulaciones para el aseo personal y formulaciones para el aseo personal obtenidas con la misma
BR9704701A (pt) Processo para a consolidação de areia
DE60022985D1 (de) Verstärkte polyamide mit hohem modul
BR0009173A (pt) Utilização de um agente anti-lixiviação
RU2003111817A (ru) Гидроизоляционная мастика

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1283699

Country of ref document: EP